Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 10;9:1571.
doi: 10.3389/fphar.2018.01571. eCollection 2018.

Microbial-Based Therapies in the Treatment of Inflammatory Bowel Disease - An Overview of Human Studies

Affiliations
Free PMC article
Review

Microbial-Based Therapies in the Treatment of Inflammatory Bowel Disease - An Overview of Human Studies

Paulo José Basso et al. Front Pharmacol. .
Free PMC article

Abstract

Inflammatory bowel disease (IBD) is a group of multifactorial and inflammatory infirmities comprised of two main entities: Ulcerative colitis (UC) and Crohn's disease (CD). Classic strategies to treat IBD are focused on decreasing inflammation besides inducing and extending disease remission. However, these approaches have several limitations such as low responsiveness, excessive immunosuppression, and refractoriness. Despite the multifactorial causality of IBD, immune disturbances and intestinal dysbiosis have been suggested as the central players in disease pathogenesis. Hence, therapies aiming at modulating intestinal microbial composition may represent a promising strategy in IBD control. Fecal microbiota transplantation (FMT) and probiotics have been explored as promising candidates to reestablish microbial balance in several immune-mediated diseases such as IBD. These microbial-based therapies have demonstrated the ability to reduce both the dysbiotic environment and production of inflammatory mediators, thus inducing remission, especially in UC. Despite these promising results, there is still no consensus on the relevance of such treatments in IBD as a potential clinical strategy. Thus, this review aims to critically review and describe the use of FMT and probiotics to treat patients with IBD.

Keywords: Crohn’s disease; Ulcerative colitis; dysbiosis; fecal microbiota transplantation; probiotics.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles

References

    1. Albenberg L., Esipova T. V., Judge C. P., Bittinger K., Chen J., Laughlin A., et al. (2014). Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology 147 1055–1063.e8. 10.1053/j.gastro.2014.07.020 - DOI - PMC - PubMed
    1. Alipour M., Zaidi D., Valcheva R., Jovel J., Martinez I., Sergi C., et al. (2016). Mucosal barrier depletion and loss of bacterial diversity are primary abnormalities in paediatric ulcerative colitis. J. Crohns Colitis 10 462–471. 10.1093/ecco-jcc/jjv223 - DOI - PMC - PubMed
    1. Allegretti J., Eysenbach L. M., El-Nachef N., Fischer M., Kelly C., Kassam Z. (2017). The current landscape and lessons from fecal microbiota transplantation for inflammatory bowel disease: past, present, and future. Inflamm. Bowel Dis. 23 1710–1717. 10.1097/MIB.0000000000001247 - DOI - PubMed
    1. Angelberger S., Reinisch W., Makristathis A., Lichtenberger C., Dejaco C., Papay P., et al. (2013). Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am. J. Gastroenterol. 108 1620–1630. 10.1038/ajg.2013.257 - DOI - PubMed
    1. Atarashi K., Tanoue T., Oshima K., Suda W., Nagano Y., Nishikawa H., et al. (2013). Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500 232–236. 10.1038/nature12331 - DOI - PubMed

LinkOut - more resources

Feedback